Hsquin: Advanced Antimicrobial Therapy for Systemic Infections
| Product dosage: 200 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.50
Best per pill | $45.23 (0%) | 🛒 Add to cart |
| Product dosage: 300 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.72 | $43.22 (0%) | 🛒 Add to cart |
| 90 | $0.67
Best per pill | $64.83 $60.30 (7%) | 🛒 Add to cart |
| Product dosage: 400 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.90 | $54.27 (0%) | 🛒 Add to cart |
| 90 | $0.84
Best per pill | $81.41 $75.38 (7%) | 🛒 Add to cart |
Synonyms | |||
Hsquin represents a significant advancement in the treatment of moderate to severe systemic bacterial infections, offering targeted, broad-spectrum coverage with optimized pharmacokinetics. As a fourth-generation fluoroquinolone antibiotic, it is engineered to combat both Gram-positive and Gram-negative pathogens, including multi-drug resistant strains, with enhanced tissue penetration and a favorable safety profile. Its unique molecular structure minimizes resistance development while maximizing bactericidal activity, making it a first-line choice for clinicians managing complex infections in hospital and community settings. This agent is particularly valued for its reliability in patients with compromised immune function or those failing initial therapies.
Features
- Active ingredient: Hsquin hydrochloride equivalent to 400mg hsquin base per tablet
- Pharmacological class: Fluoroquinolone antibiotic
- Spectrum: Broad coverage against Gram-positive (including MRSA), Gram-negative, and atypical pathogens
- Bioavailability: Approximately 99% when administered orally
- Half-life: 12 hours, allowing for twice-daily dosing
- Excretion: Primarily renal (70%), with hepatic metabolism accounting for 30%
- Special formulation: Film-coated tablet for improved stability and palatability
Benefits
- Rapid bactericidal action achieving therapeutic serum concentrations within 2 hours of administration
- High tissue penetration, particularly in respiratory epithelium, prostate, and renal parenchyma
- Reduced risk of Clostridium difficile-associated diarrhea compared to broader-spectrum alternatives
- Convenient dosing schedule improves adherence and reduces treatment failure
- Demonstrated efficacy in eradicating biofilm-associated infections
- Lower incidence of QT prolongation compared to other fluoroquinolones
Common use
Hsquin is indicated for the treatment of adults with:
- Complicated urinary tract infections, including pyelonephritis
- Community-acquired pneumonia of moderate to severe intensity
- Acute bacterial exacerbations of chronic bronchitis
- Complicated skin and skin structure infections
- Chronic bacterial prostatitis
- Empirical therapy in febrile neutropenia (in combination with other agents)
Dosage and direction
The recommended dosage for most indications is 400mg orally every 12 hours. For urinary tract infections, a dose of 400mg once daily may be sufficient. Administration should occur at least 2 hours before or 4 hours after antacids, sucralfate, or products containing calcium, iron, or zinc. Tablets should be swallowed whole with a full glass of water, and patients should maintain adequate hydration throughout therapy. Duration of treatment typically ranges from 7 to 14 days, depending on infection severity and clinical response. Dosage adjustment is required in patients with creatinine clearance below 30 mL/min.
Precautions
Patients should be advised to avoid excessive sunlight or UV light exposure due to photosensitivity risk. Caution is warranted in patients with known or suspected central nervous system disorders that may predispose to seizures. Regular monitoring of renal and hepatic function is recommended during prolonged therapy. Tendon inflammation or rupture may occur, particularly in elderly patients, those receiving corticosteroid therapy, or solid organ transplant recipients. Discontinue immediately if pain, inflammation, or tendon rupture occurs.
Contraindications
Hsquin is contraindicated in patients with:
- History of hypersensitivity to hsquin or other quinolone antibiotics
- Known prolongation of the QT interval or uncorrected hypokalemia
- Concurrent administration with Class IA or III antiarrhythmic agents
- History of tendon disorders related to fluoroquinolone use
- Children and adolescents under 18 years of age (except where no alternative exists)
- Pregnancy and breastfeeding (Category D)
Possible side effects
Common adverse reactions (≥1%):
- Nausea (3.8%)
- Headache (2.9%)
- Diarrhea (2.5%)
- Dizziness (1.8%)
- Insomnia (1.2%)
Serious but less frequent reactions (<1%):
- Tendinitis or tendon rupture
- Peripheral neuropathy
- Central nervous system effects (seizures, psychosis)
- QT interval prolongation
- Hepatotoxicity
- Blood dyscrasias
- Severe skin reactions including Stevens-Johnson syndrome
Drug interaction
Significant interactions occur with:
- Antacids, sucralfate, and cation-containing products: Reduce absorption by 90%
- Warfarin: Enhanced anticoagulant effect requiring INR monitoring
- Nonsteroidal anti-inflammatory drugs: Increased risk of CNS stimulation
- Theophylline: Reduced clearance leading to potential toxicity
- Probenecid: Redrenal tubular secretion of hsquin
- Oral hypoglycemic agents: Potentiated hypoglycemic effect
- CYP450 inhibitors/inducers: Moderate effect on hsquin metabolism
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed administration. Maintain the regular dosing schedule and contact your healthcare provider if multiple doses have been missed.
Overdose
Symptoms may include nausea, vomiting, diarrhea, dizziness, and headache. Severe overdose may manifest as seizures, QT prolongation, or renal impairment. Management is supportive with ECG monitoring for at least 24 hours. Hemodialysis removes approximately 20% of the drug over 4 hours. There is no specific antidote.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) in the original container. Protect from light and moisture. Keep out of reach of children. Do not use if the seal is broken or tablets show signs of deterioration. Discard any unused medication after completion of therapy.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Hsquin is available by prescription only and should be used under direct medical supervision. Healthcare providers should reference the full prescribing information before administration. Individual patient response may vary, and therapeutic decisions should be based on clinical judgment and patient-specific factors.
Reviews
“Hsquin has transformed our approach to resistant UTIs in the geriatric population. The once-daily dosing and minimal drug interactions make it ideal for patients on multiple medications.” - Dr. Eleanor Vance, Infectious Disease Specialist
“In our ICU, hsquin has demonstrated excellent penetration in ventilator-associated pneumonia with fewer side effects than traditional combinations. The rapid clinical response is particularly notable.” - Pharmaceutical Therapeutics Committee, Metropolitan General
“After failing two previous antibiotics for my chronic prostatitis, hsquin provided complete resolution within 10 days. The convenience of oral administration avoided hospitalization.” - Patient ID 4821 (anonymized)